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momobilization protocols has not been clearly described. We
developed a chemomobilization algorithm using a 2-day
infusion of etoposide at 300 mg/m2 followed by GCSF. The
algorithm included a predetermined decision point for the
addition of plerixafor for poormobilizers. The purpose of this
study is to prospectively evaluate the safety and efﬁcacy of
this algorithm in patients undergoing chemomobilization
ahead of autologous HSCT.
Methods: Patients underwent chemomobilization using
etoposide at a dose of 300 mg/m2 daily for 2 days, followed
by ﬁlgrastim 10 mcg/kg starting on day 3. At day 12, patients
began WBC screening, and once the WBC count rose to > 2 x
109/L, CD34+ screening began. If the CD34+ count was >20/
uL, patients proceeded to collection. If the CD34+ count was
<20/uL, plerixafor was added. Patients who required pler-
ixafor to reach a CD34+count >20/uL remained on plerixafor
daily until their collection goal was met. The CD34+ stem cell
collection goal was 4 x 106 cells/kg, with a minimum
requirement of 2 x 106 cells/kg to proceed to HSCT.
Results: To date, 21 patients (14 lymphoma, 5 multiple
myeloma, and 2 other) have been treated with our algorithm.
Four of the ﬁve patients withmultiple myeloma had received
> 6 cycles of lenalidomide. Of the 21 patients, 18 were
successfully mobilized using etoposide plus ﬁlgrastim alone.
The 3 patients who had inadequate CD34+ mobilizationwith
etoposide plus ﬁlgrastim all responded to the addition of
plerixafor. To date, 16 of the 21 patients have successfully
been transplanted, with the remaining 5 expected to
complete SCT within the next month. Patients collected with
an average of 1.4 apheresis sessions and collected an average
of 6.23 x 106 CD34+ cells/kg. Four patients (19%) were
hospitalized due to febrile neutropenia during the course of
mobilization.
Conclusion: We demonstrated a successful algorithm-based
approach to chemomobilization that included a pre-
determined strategy to include plerixafor for poor mobi-
lizers.123
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Background: MMF is hepatically metabolized to mycophe-
nolic acid (MPA) glucuronide and reconverted to an active
MPA by colonic bacteria (Shaw et al, Clin Biochem 2001).
MPA area under the curve and steady state concentration
(Css) predict acute rejection in solid organ transplant. MMF
at 900 mg/m2 q6h results in (MPA) Css concentrations
between 4.73 (2.22) to 6.54 (3.55) mcg/mL in pediatric
recipients post-AlloSCT (Bhatia/Militano/Cairo, BBMT 2010).
Objective: To determine safety/efﬁcacy of MMF at 900 mg/
m2/dose q8h in combination with tacrolimus in pediatric
AlloSCT recipients.
Methods: GVHD prophylaxis included tacrolimus 0.03-0.04
mg/kg/day IVCI on Day -1 or 1st day of conditioning(target range 10-20 ng/mL) and MMF 900 mg/m2 (max 1.5
g/dose) IV/PO q8h starting on Day +1. MPA trough
concentrations were obtained if toxicity or acute GVHD
(aGVHD) was suspected. AGVHD, chronic GVHD (cGVHD)
and overall survival (OS) were determined by Kaplan-
Meier method.
Results: 15 pts: mean age 9.1 yrs (range 0.8-17.2); M:F 13:2;
7 pts non-malignant & 8 with malignant disease; donor
source: 4 related BM, 5 MUD, 5 UCB, 1 haploSCT; condi-
tioning: 8 myeloablative and 7 reduced intensity. Median
time to myeloid and platelet engraftment was 17 and 29
days, respectively. Probability of Grade II-IV aGVHD and
limited + extensive cGVHD was 35.3% (CI95:5.7-68.5) and 0%,
respectively. Probability of 1-year OS was 78.7% (CI95: 38.0-
94.2). Four pts had MPA trough levels prior to day +30 (mean
trough 1.22 mcg/mL; range <0.5e2). Eight pts had 15 MPA
trough concentrations reported Day +30 to Day +100 (mean
trough 4.2 mcg/mL; range < 0.5e7.9). Four of 8 (50%)
patients had MPA trough levels above the recommended
maximum of 3.5 mcg/mL during Day +30 to +100 post-
transplant period.
Conclusion: MMF at 900 mg/m2 q8h in combination with
tacrolimus appears effective for prevention of aGVHD and
cGVHD in the pediatric AlloSCT recipients. MMF dosing
and pharmacokinetics in the later post-SCT period (Day
+30 to Day +100) deserve further attention due to
increased potential for high MPA trough concentrations.
The potential difference in MPA trough concentration
between early (<Day +30) or late post-SCT period, could
be due to improved mucosal healing following condi-
tioning that leads to improved drug absorption and
enterohepatic recirculation. Based on these results, we
recommend MMF dose reduction and monitoring MPA
trough concentrations in the late post-AlloSCT period to
avoid potential toxicity.124
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Background: Invasive fungal infections are a signiﬁcant
cause of morbidity and mortality in recipients of hemato-
poietic cell transplantation (HCT), warranting antifungal
prophylaxis as a standard of care. A number of options are
available for prophylaxis, but none have been found to be
ideal. Due to its broad spectrum of activity and multiple
dosage forms, voriconazole remains one of the commonly
used agents in this setting. It's well known that there is
wide inter and intra-patient variability in voriconazole
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CYP450 polymorphism, CYP450-2C19. The aim of our pilot
study was to determine effects of therapeutic drug moni-
toring (TDM) and genotyping in achieving desired vor-
iconazole levels for antifungal prophylaxis in the post HCT
period.
Methods: All patients undergoing HCT at Cincinnati Child-
ren's Hospital Medical Center who received voriconazole
between February 2012 and September 2012 were prospec-Figure 1.tively followed. Voriconazole concentrations were drawn
weekly and adjusted until between 1 mg/L and 5.5 mg/L.
Mutational analyses of the most commonmutation CYP2C19
*2 were performed on all patients to determine their geno-
type. All patients were monitored for common side effects of
voriconazole.
Results: Twenty-ﬁve patients received voriconazole as anti-
fungal prophylaxis for a median of 49 days (range 15-196). In
patients with a wild type genotype the median time to
therapeutic level was 30 days, for heterozygotes 47 days and
11 days for patients with variant genotype. Time and dose
required to reach adequate levels showed a trend towards
correlation with CYP2C19 genotyping (Fig 1). Voriconazole
levels showed larger inter-patient variability in wild-type
patients (Fig 1). Five patients had elevations three times
the upper limit of normal, 1 was discontinued fromvoriconazole therapy. Two patients had levels >5.5 mg/L; 1
showed clinical adverse effects.
Conclusions: Our pilot study demonstrates the importance
of rigorous TDM and potential utilization of CYP2C19 gen-
otyping in selecting appropriate voriconazole dosing for
patients. Despite a small number of patients, it appears that
traditional voriconazole dosing of 4 mg/kg/dose every 12
hours may not be sufﬁcient to achieve levels appropriate
for prophylaxis for the majority of patients in the pop-
ulation, leaving such patients susceptible to fungal infec-
tions during their post HCT course, something that we plan
to address in our future studies using genotype speciﬁc
initial dosing.
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Immune dysregulation resulting in autoimmune cyto-
penia is a serious complication of allogeneic stem cell
transplants (SCT). There are few treatment options when
ﬁrst-line and second-line therapies such as steroids, ritux-
imab and IVIG fail to work. Bortezomib is toxic to malig-
nant and normal plasma cells, and has been used to
decrease allo-antibody titers in sensitized solid organ
transplant recipients. We describe a pediatric patient with
history of chronic granulomatous disease who underwent
a matched unrelated donor bone marrow transplant and
developed secondary autoimmune hemolytic anemia
(AIHA) 5 months later. The AIHA transiently improved after
treatment with steroids, rituximab and IVIG. However, after
4 months there was an exacerbation of AIHA, and evidence
of broader autoimmunity with neutropenia, thrombocyto-
penia, and minimal change nephrotic syndrome. In addi-
tion, opportunistic infection with adenovirus and atypical
mycobacteria developed. There was no response of the
immune cytopenias or nephrosis to high-dose steroids,
IVIG, another 4-week course of rituximab, and plasma-
pheresis. Four doses of bortezomib 1.3mg/m2 IV on days +1,
+4, +8, +11 were administered, with concurrent steroids
and plasmapherisis. Bortezomib was well-tolerated with
transient decrease in neutrophil count. Within 1 month,
the reticulocyte count, haptoglobin, bilirubin, and direct
antiglobulin test normalized, accompanied by a decline in
transfusion requirement, resolution of neutropenia, and
improvement in nephrosis. Anemia and thrombocytopenia
did not completely resolve because of adenoviral hemor-
rhagic cystitis, and he ultimately died as a result of the
opportunistic infections. In patients whose autoimmune
cytopenia does not resolve with rituximab, treatment with
bortezomib can rapidly eliminate autoantibody producing
B-cells and plasma cells. Earlier institution of therapy may
result in disease control and avoid the complications of
prolonged immune suppression.
